| human | Q5 |
| P856 | official website | http://research.mc.ntu.edu.tw/web/Teacher!one.action?tid=589 |
| P496 | ORCID iD | 0000-0002-4686-7019 |
| P1153 | Scopus author ID | 8287897400 |
| P69 | educated at | National Taiwan University | Q32746 |
| Ohio State University | Q309331 | ||
| P108 | employer | National Taiwan University | Q32746 |
| National Taiwan University Hospital | Q1418766 | ||
| P106 | occupation | researcher | Q1650915 |
| Q39003862 | A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. |
| Q39612275 | Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells |
| Q89142829 | Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation |
| Q39043713 | Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition. |
| Q39442742 | Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. |
| Q37160844 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway |
| Q39577867 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. |
| Q39395326 | CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells |
| Q34577215 | Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome |
| Q38710692 | Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition |
| Q36088163 | Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells |
| Q39425929 | Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. |
| Q39414944 | Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. |
| Q46431072 | Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells |
| Q34467228 | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. |
| Q35885030 | Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma |
| Q39633968 | Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells |
| Q53169400 | Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. |
| Q39239414 | Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma |
| Q39013030 | Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. |
| Q39916403 | OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma |
| Q38987827 | Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells |
| Q41194460 | Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner |
| Q36177646 | Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer |
| Q48190361 | RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. |
| Q39289959 | SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells. |
| Q54978298 | Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma. |
| Q39585554 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma |
| Q58215137 | Sorafenib Enhances Radiation-Induced Apoptosis in Hepatocellular Carcinoma by Inhibiting STAT3 |
| Q41127816 | Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells |
| Q35740334 | Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition |
| Q36629288 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody |
| Q39550758 | Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. |
| Q39649432 | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. |
| Q35847734 | Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance |
| Q39774803 | Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation |
| Q35000235 | Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells |
Search more.